Last reviewed · How we verify
NCT05443438
Where's the Wif? Referent Selection and Retention
NA trial testing Modality - 3D-2D in Healthy in 212 participants. Completed in 30 April 2025.
29 March 2025
Quick facts
| Lead sponsor | Oklahoma State University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 212 |
| Start date | 7 April 2022 |
| Primary completion | 29 March 2025 |
| Estimated completion | 30 April 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Modality - 3D-2D
- Modality - 2D-3D
- Modality - 2D-2D
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Oklahoma State University
Who can join
Adults 17 Months to 30 Months, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this work is to address increasing concerns about young children's digital media exposure and language outcomes by testing how the times course of word learning unfolds in digital environments and the cascading impact of digital media on vocabulary outcomes. The findings will have important implications for understanding when and where optimal word learning from media can occur.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05443438
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Modality - 3D-2D
Trials testing the same drug.
- NCT05443399 — What Makes a Cup, a Cup? Generalizing Novel Words · NA · completed
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Oklahoma State University trials
Trials by the same sponsor.
- NCT06970457 — The Interaction of Body Composition, Sex Hormones and Exercise in Men · NA · recruiting
- NCT06840431 — Randomized Control Trial of the Co-Parenting for Resilience Program · NA · enrolling by invitation
- NCT05977192 — Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination · NA · completed
- NCT06518863 — Ultra-Processed Foods and Executive Function · NA · completed
- NCT06310603 — Determinants and Outcomes of High vs. Low Ultra-processed Feeding · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05443438 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Oklahoma State University
- Last refreshed: 14 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05443438.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing